Related Experiment Video
Updated: Sep 5, 2025
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Saswati Das1, Raveen Stephen Stallon Illangeswaran1, Smitha Ijee2
1Department of Clinical Haematology, Christian Medical College; Department of Biotechnology, Thiruvalluvar University.
Abstract:
Understanding clinically relevant driver mechanisms of acquired chemo-resistance is crucial for elucidating ways to circumvent resistance and improve survival in patients with acute myeloid leukemia (AML). A small fraction of leukemic cells that survive chemotherapy have a poised epigenetic state to tolerate chemotherapeutic insult. Further exposure to chemotherapy allows these drug persister cells to attain a fixed epigenetic state, which leads to altered gene expression, resulting in the proliferation of these drug-resistant populations and eventually relapse or refractory disease. Therefore, identifying epigenetic modulations that necessitate the survival of drug-resistant leukemic cells is critical. We detail a protocol to identify epigenetic modulators that mediate resistance to the nucleoside analog cytarabine (AraC) using pooled shRNA library screening in an acquired cytarabine-resistant AML cell line. The library consists of 5,485 shRNA constructs targeting 407 human epigenetic factors, which allows high-throughput epigenetic factor screening.
Insights
Identifying epigenetic changes is key to overcoming chemotherapy resistance in acute myeloid leukemia (AML). This study developed a method to find epigenetic factors driving resistance to cytarabine (AraC), aiming to improve patient survival.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Acquired chemo-resistance in acute myeloid leukemia (AML) poses a significant clinical challenge, leading to disease relapse and refractory states.
- Leukemic cells surviving chemotherapy can enter a drug-tolerant epigenetic state, which can be further modified to establish stable resistance.
- Identifying the epigenetic mechanisms underlying this resistance is critical for developing strategies to improve patient outcomes.
Purpose of the Study:
- To develop and implement a high-throughput screening protocol to identify epigenetic modulators conferring resistance to cytarabine (AraC) in AML.
- To understand the role of epigenetic alterations in the survival and proliferation of drug-resistant leukemic cells.
Main Methods:
- Utilized a pooled shRNA library targeting 407 human epigenetic factors for high-throughput screening.
- Employed an acquired cytarabine-resistant AML cell line to identify epigenetic factors mediating resistance.
- Developed a protocol for screening epigenetic modulators involved in chemo-resistance.
Main Results:
- Successfully established a protocol for identifying epigenetic modulators of cytarabine resistance.
- The screening approach allows for the high-throughput analysis of numerous epigenetic factors.
- This method can pinpoint specific epigenetic targets crucial for leukemic cell survival under chemotherapeutic pressure.
Conclusions:
- Epigenetic modifications play a pivotal role in the development of acquired chemo-resistance in AML.
- The developed screening protocol provides a powerful tool for discovering novel epigenetic targets to overcome cytarabine resistance.
- Circumventing these identified epigenetic mechanisms holds promise for improving therapeutic strategies and patient survival in AML.
